MindMed has capitalized on its recent market success to raise new capital on more favorable terms.
Psychedelics
Release: Health and Wellness Industry Tastemaker Jon Bier Joins Mind Cure's (CSE: MCUR) Advisory Board
Mr. Bier is a communications and strategy expert who has played a key role in building brands such as Four Sigmatic and WHOOP
Numinus Commences Psilocybe Mushroom Cultivation
Numinus commences psilocybin cultivation as part of its "ecosystem approach" to psychedelic drug therapy.
Mind Cure Assembles Cast For Psychedelic Drug Success
After a series of significant corporate appointments, Mind Cure is poised to advance its operations.
Mind Cure Welcomes Dr. Jason Wallach to Scientific Advisory Board
Mind Cure's latest addition to its Scientific Advisory Board is a noted expert in psychedelic medicine, published researcher, and professor of pharmacology.
Mydecine Innovations Group Announces Filing of Provisional Patent for the Treatment of PTSD with Psilocybin
Mydecine's new patent application may lead to a way to derive the medicinal benefits of psilocybin at lower doses.
Upstart Mind Cure (CSE:MCUR) Targets Disrupting $300 Billion Industry
The mental healthcare industry is ripe for innovation. And companies like Mind Cure (CSE: MCUR), which recently completed its IPO, are set to lead the way.
Prominent Psychedelic Medicine Researcher Added To Mind Cure Team
This is Mind Cure's third high-profile addition to its Scientific Advisory Board in the last week.
Mind Cure Welcomes Award-Winning Journalist and Science Researcher Hamilton Morris to Advisory Board
Noted psychedelic drug expert, Hamilton Morris, is the latest addition to Mind Cure's advisory board.
Mind Cure Adds 'Hamilton's Pharmacopiea' Creator As Scientific Advisor
Mind Cure adds a thought leader in the psychedelics space to its Advisory Board.
Field Trip Psychedelics RTO Provides Exciting New Investing Option
Field Trip Psychedelics is targeting a $16 billion treatment market with its ketamine-assisted psychotherapy clinics.
MindMed Partners with NYU Langone Medical Center to Launch Groundbreaking Training Program for Psychedelic Therapies and Medicines
This is MindMed's first step in establishing a Center for Psychedelic Medicine at NYU Langone Health.
Field Trip Health Ltd. to Commence Trading on the CSE on October 6 Under Ticker Symbol FTRP
Field Trip will make its trading debut on Tuesday.
Field Trip Health Ltd. Completes Reverse Take-Over Transaction and Prepares for Listing on the Canadian Securities Exchange
Field Trip to commence trading October 7th on the CSE, symbol "FTRP".
Dr. Dan Engle Joins Mind Cure's (CSE: MCUR) Advisory Board
The world-renowned transformative medicine expert will contribute towards Mind Cure's work in the realm of psychedelic research, treatment and integration